MPS ANTIBODY DISCOVERY
MAbs against GPCRs , Ion Channels and Transporters
>95% success
20+ years expertise focused on membrane proteins
MPS Antibody Discovery: Providing Access to ‘Undruggable’ Targets

Monoclonal antibodies against membrane protein targets are notoriously difficult to isolate. MPS is the only antibody discovery platform specifically built for multipass membrane protein targets including GPCRs, ion channels and transporters.
Our technologies enable robust immune responses against conserved proteins and harness deep screening technologies, such as phage display, to discover rare and functional antibodies.
“Access to Integral Molecular’s capabilities complements our ability to advance our therapeutic pipeline, which is dedicated to delivering novel antibody therapeutics to patients.”
The Industry Leader: Delivering Preclinical Antibodies With >95% Success
Our Process: Proprietary Methods to Deliver Lead Candidates

Deliverables: What MPS Services Routinely Provide to Our Partners

Large panels of antibodies with diverse epitopes obtained through deep screening




Validated and highly characterized preclinical-ready antibodies
“We have been impressed by Integral Molecular’s membrane protein expertise and their proven record in discovering antibodies against membrane proteins.”
MPS Success Stories: Trusted by Our Partners

Featured Case Studies
Publications Featuring the MPS Antibody Discovery Platform
Frequently Asked Questions
The MPS Antibody Discovery platform overcomes three key barriers to enable success; presenting native epitopes, making the target highly immunogenic, and generating MAbs against diverse epitopes. Optimizing for antigen and a strategic immunization are critically important for downstream success. The MPS Antibody Discovery platform overcomes challenges associated with membrane proteins such as poor expression, trafficking, toxicity, and preservation of native conformation. Specialized tools, technology, and expertise includes proprietary expression vectors, targeted mutagenesis strategies, and premium reagents for exceptional outcomes. As the inventors of Lipoparticles, rest assured that your project begins with the highest quality antigen available for immunization and discovery. Our innovative immunization protocols may include the use of divergent species, DNA, mRNA, and Lipoparticles. This system is proven to elicit a robust, diverse, and focused immune responses on relevant extracellular epitopes. We routinely isolate high-affinity, humanized mAbs against highly conserved membrane protein targets, with desirable characteristics including state-specific binding and functional activity.
The MPS platform delivers fully humanized MAbs. Healthy, outbred, wild-type chickens are excellent immunization hosts, producing robust immune responses and offering excellent opportunities for MAb diversity while overcoming homology challenges associated with mammalian hosts. Chicken antibody frameworks are highly amenable to humanization. With our Humanized Chicken Antibody Discovery technology (hCAT), antibody CDR’s from responsive chickens are humanized prior to the creation of immune libraries used for phage panning. Hits isolated during screening are fully humanized, eliminating the time and cost required for downstream engineering. The result is high affinity, fully humanized MAbs ready for preclinical characterization.
Alternatively, we are a Certified Service Provider of Alloy Therapeutics, offering immunization in ATX-GxTM transgenic, immunocompetent mice which produce human antibodies.
The final deliverable of an MPS Antibody Discovery project is usually a panel of highly specific, diverse, and functional MAbs that meet the customer’s specifications. Using our MPS Antibody Discovery platform, we have a very high success rate (>95%) in delivering such MAb panels. In addition to the final deliverable, customers receive 4 progress reports during their MPS project:
- Target Expression Report – Summarizes target expression after engineering to validate immunization, panning, and screening constructs, and sufficient target incorporation into Lipoparticles
- Serum Reactivity Report – Summarizes the immune response of each animal to the target protein
- Clone Screen Report – Summarizes MAb selection results and the diversity of discovered MAbs
- MAb Validation and Sequence Report –Sequences are reported with a summary of target-specific binding validation by flow cytometry in final preferred format (eg., IgG). Purified, ready to use IgG may be provided for customer evaluation.